14:20 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

DISEASE CATEGORY: Cancer INDICATION: Mantle cell lymphoma (MCL); B cell lymphoma Patient sample, cell culture and mouse studies identified an OXPHOS complex I inhibitor that could help treat MCL and B cell lymphoma that are...
13:46 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Renal cancer; lung cancer Cell culture and mouse studies suggest inhibiting PGD alone or in combination with OXPHOS complex I inhibition could help treat renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC),...
04:50 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ImmunoMet starts Phase I of IM156 for solid tumors

ImmunoMet Therapeutics Inc. (Houston, Texas) began a Phase I trial of IM156 to treat solid tumors in up to 36 patients. The primary endpoint is to determine the maximum tolerated dose (MTD) and recommended Phase...
18:14 , Jun 16, 2017 |  BioCentury  |  Emerging Company Profile

Metabolic regulation

ImmunoMet Therapeutics Inc. is developing a portfolio of biguanide derivatives that have the anticancer properties of metformin but are better optimized for the indication. Some starve drug-resistant cancers by blocking a metabolic pathway they rely...